Surf Wiki
Save to docs
general/2-aminoindanes

From Surf Wiki (app.surf) — the open knowledge base

Indacaterol

Chemical compound

Chemical compound

| Drugs.com = | elimination_half-life =

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.

Medical uses

A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists.

ReceptorKi
β16.21
β27.36
β35.48

History

It was approved by the European Medicines Agency (EMA) under the brand name Onbrez Breezhaler on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the brand name Arcapta Neohaler, on July 1, 2011. In 2016, Novartis licensed its U.S. commercial rights for Arcapta Neohaler to Sunovion Pharmaceuticals.

References

References

  1. (1 April 2020). "Arcapta Neohaler (indacaterol) inhalation powder Initial U.S. Approval: 2011".
  2. (17 September 2018). "Onbrez Breezhaler EPAR".
  3. (17 September 2018). "Oslif Breezhaler EPAR".
  4. (17 September 2018). "Hirobriz Breezhaler EPAR".
  5. (July 2005). "Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease". Expert Opin Investig Drugs.
  6. (May 2007). "Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma". Eur. Respir. J..
  7. "Indacaterol (Arcapta Neohaler) National Drug Monograph".
  8. (2015). "Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease". Reviews.
  9. (May 2006). "In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action". The Journal of Pharmacology and Experimental Therapeutics.
  10. "European Public Assessment Report for Onbrez Breezhaler".
  11. (2011-07-01). "FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease". U.S. Food and Drug Administration.
  12. (13 August 2013). "Drug Approval Package: Arcapta Neohaler (indacaterol maleate) NDA #022383".
  13. (22 December 2016). "Sunovion, Novartis ink licensing deal for inhaled COPD drugs".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

2-aminoindanes phenylethanolamines long-acting-beta2-adrenergic-agonists drugs-developed-by-novartis quinolinols 2-quinolones
Want to explore this topic further?

Ask Mako anything about Indacaterol — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report